| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5700243 | Clinical Oncology | 2009 | 9 Pages |
Abstract
Androgen deprivation therapy is widely used in a number of different settings in the treatment of prostate cancer. This overview will look at the current evidence for the potential development of metabolic syndrome and cardiovascular disease as a consequence of this therapy, and highlight strategies aimed at their prevention. The relationship between metabolic syndrome and prostate cancer development will also be examined.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
J.P. Nobes, S.E.M. Langley, R.W. Laing,